Latest Breaking News On - Spruce biosciences - Page 5 : comparemela.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Spruce

NEW YORK, March 23, 2024 (GLOBE NEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Spruce Biosciences, Inc. (“Spruce” or the “Company”) (NASDAQ: SPRB). Such investors are

New yorkUnited statesFrance generalCity ofUnited kingdomTel avivDanielle peytonLos angelesAbrahaml pomerantzSpruce biosciences incSpruce biosciencesAdult classic congenital adrenal hyperplasiaSevere hyperandrogenemiaNation world

Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates

CAHmelia-203 Study of Tildacerfont in Adult Classic Congenital Adrenal Hyperplasia with Severe Hyperandrogenemia Did Not Meet Primary Efficacy Endpoint Positive Data from CAHptain-205 Study of.

Javier szwarcbergSpruce biosciences incDevelopment rd expensesExchange commissionDrug administrationSpruce biosciencesChief executive officerAdult classic congenital adrenal hyperplasiaPediatric classicCash equivalentsKaken pharmaceuticalOperating expensesPrivate securities litigation reform actEnded december

Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts (NASDAQ:SPRB)

Guggenheim starts Spruce Biosciences at buy, cites near-term catalysts (NASDAQ:SPRB)
seekingalpha.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from seekingalpha.com Daily Mail and Mail on Sunday newspapers.

Spruce biosciences

Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Spruce Biosciences, Inc. , a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today.

Javier szwarcbergHealthcare life sciences conference onSpruce biosciences incSpruce biosciencesChief executive officerAnnual healthcare life sciences conference

Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia

100 Patients Enrolled, Exceeding Target Enrollment of 90 Patients Topline Results for CAHmelia-204 Anticipated in the Third Quarter of 2024 .

Javier szwarcbergSpruce biosciences incDrug administrationExchange commissionSpruce biosciencesChief executive officerCongenital adrenal hyperplasiaPrivate securities litigation reform act